Published in Schizophr Res on August 01, 2001
Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull (2009) 2.90
Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull (2005) 2.50
Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv Psychiatry (2010) 1.71
Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev (2011) 1.49
Ten good reasons to consider biological processes in prevention and intervention research. Dev Psychopathol (2008) 1.41
Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry (2010) 1.36
Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother (2010) 1.10
Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull (2008) 1.07
Early and broadly defined psychosis risk mental states. Schizophr Res (2010) 1.01
Early intervention in psychotic disorders: Challenges and relevance in the Indian context. Indian J Psychiatry (2010) 0.85
Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia? J Neural Transm (Vienna) (2007) 0.84
A brief taxometrics primer. J Clin Child Adolesc Psychol (2007) 0.84
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol Psychiatry (2013) 0.84
Genealogy of instruments for prodrome evaluation of psychosis. Front Psychiatry (2013) 0.82
Treatment implications of the schizophrenia prodrome. Curr Top Behav Neurosci (2010) 0.82
The prodromal stage of psychotic illness: observation, detection or intervention? J Psychiatry Neurosci (2003) 0.81
Ethical concerns in schizophrenia research: looking back and moving forward. Schizophr Bull (2005) 0.79
Treating early psychosis: who, what, and when? Dialogues Clin Neurosci (2005) 0.79
Interaction of social role functioning and coping in people with recent-onset attenuated psychotic symptoms: a case study of three Chinese women at clinical high risk for psychosis. Neuropsychiatr Dis Treat (2015) 0.76
What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general? Lancet Psychiatry (2015) 0.76
Ethical considerations when treating patients with schizophrenia. Psychiatry (Edgmont) (2008) 0.75
Cognitive behavioral therapy in prodromal psychosis. Curr Pharm Des (2012) 0.75
Reduced prefrontal gray matter volume and reduced autonomic activity in antisocial personality disorder. Arch Gen Psychiatry (2000) 5.26
The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry (1997) 4.79
Standardized remission criteria in schizophrenia. Acta Psychiatr Scand (2006) 3.29
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry (2000) 2.93
Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry (2007) 2.70
Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry (1982) 2.43
Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry (1982) 2.42
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry (1997) 2.29
Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry (2005) 2.29
Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry (2010) 2.21
Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand (2013) 2.08
Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med (1989) 2.07
Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry (1983) 1.92
Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull (1988) 1.88
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry (1997) 1.86
Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry (2000) 1.64
Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch Gen Psychiatry (1999) 1.61
Clozapine: guidelines for clinical management. J Clin Psychiatry (1989) 1.60
Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) (1987) 1.60
Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry (1992) 1.55
Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality. Schizophr Bull (1994) 1.54
The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand (1990) 1.49
HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry (1990) 1.46
Polydipsia and tardive dyskinesia in chronic psychiatric patients--related disorders? Am J Psychiatry (1993) 1.43
Serum lithium levels and psychosocial function in patients with bipolar I disorder. Am J Psychiatry (1996) 1.42
Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch Gen Psychiatry (1992) 1.40
The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol (1990) 1.39
Psychopharmacological screening criteria. APA Committee on Research on Psychiatric Treatments. J Clin Psychiatry (1992) 1.39
Update on the clinical efficacy and side effects of clozapine. Schizophr Bull (1991) 1.39
Effects of pudendal nerve injury in the female rat. Neurourol Urodyn (2000) 1.36
Risperidone: efficacy and safety. Schizophr Bull (1995) 1.35
Olanzapine (Zyprexa):characteristics of a new antipsychotic. Expert Opin Investig Drugs (1997) 1.32
Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry (1994) 1.29
Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl (2009) 1.27
Autonomic stress reactivity and executive functions in successful and unsuccessful criminal psychopaths from the community. J Abnorm Psychol (2001) 1.26
Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia. Schizophr Res (2000) 1.23
Tuberculosis after jejunoileal bypass for obesity. JAMA (1975) 1.21
Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry (1995) 1.19
Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull (1986) 1.17
Verbal memory impairment correlates with hippocampal pyramidal cell density. Neurology (1990) 1.14
Prospective study of tardive dyskinesia incidence in the elderly. JAMA (1991) 1.13
Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry (2011) 1.13
Treatment of schizophrenia. Schizophr Bull (1987) 1.12
Specificity in the correlation of verbal memory and hippocampal neuron loss: dissociation of memory, language, and verbal intellectual ability. J Clin Exp Neuropsychol (1992) 1.12
Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull (1988) 1.11
Clozapine and weight gain. J Clin Psychiatry (1994) 1.09
The use of higher-dose antipsychotic medication. Comment on the Royal College of Psychiatrists' consensus statement. Br J Psychiatry (1994) 1.07
Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry (2011) 1.07
Investigation of frontal lobe subregions in first-episode schizophrenia. Psychiatry Res (1999) 1.06
Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull (1993) 1.05
Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry (1998) 1.04
Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry (1988) 1.03
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry (1995) 1.01
GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Mol Psychiatry (2010) 1.00
Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry (1982) 0.99
Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy. Eur J Surg Oncol (2008) 0.99
Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J (2009) 0.98
Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry (1982) 0.95
Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry (1996) 0.94
The neural substrate of memory impairment demonstrated by the intracarotid amobarbital procedure. Arch Neurol (1991) 0.93
Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. Schizophr Res (1992) 0.92
Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatry (2001) 0.91
Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull (1997) 0.91
The dexamethasone suppression test in depression. Clin Neuropharmacol (1983) 0.91
Neuromuscular effects of monoamine oxidase inhibitors. Adv Neurol (1986) 0.90
Prediction of relapse in schizophrenia. Arch Gen Psychiatry (1987) 0.89
Problems of compliance in the outpatient treatment of schizophrenia. J Clin Psychiatry (1983) 0.89
Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull (1984) 0.89
Naloxone reduces cigarette smoking. Life Sci (1980) 0.89
Elevated levels of cognitive-perceptual deficits in individuals with a family history of schizophrenia spectrum disorders. Schizophr Res (2000) 0.87
Compliance issues in outpatient treatment. J Clin Psychopharmacol (1985) 0.87
Needle aspiration of nonfunctioning parathyroid cysts. Am Surg (1990) 0.87
The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med (2010) 0.87
Side effects of antipsychotic drugs. Avoiding and minimizing their impact in elderly patients. Postgrad Med (2000) 0.86
Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res (1997) 0.86
Outcome study of first-episode psychosis. I: Relapse rates after 1 year. Am J Psychiatry (1986) 0.85
Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry (1996) 0.85
Relationship between the B-mitten EEG pattern and tardive dyskinesia. A pilot control study. Arch Gen Psychiatry (1979) 0.85
A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol (1982) 0.85
Medical complications of new antipsychotic drugs. Schizophr Bull (1996) 0.84
Role of nutrition support during induction chemoradiation therapy in esophageal cancer. JPEN J Parenter Enteral Nutr (1998) 0.84
An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Res (1992) 0.84
Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. J Clin Psychiatry (1986) 0.84
Epidemiology of tardive dyskinesia. Clin Neuropharmacol (1983) 0.83
Attitudinal changes of involuntarily committed patients following treatment. Arch Gen Psychiatry (1983) 0.83
Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull (1990) 0.83
Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. Arch Gen Psychiatry (1985) 0.83
Diabetes and development of tardive dyskinesia. Am J Psychiatry (1993) 0.83
Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania. J Child Adolesc Psychopharmacol (2001) 0.83
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. J Clin Psychopharmacol (1999) 0.83
Cerebral morphometry and clozapine treatment in schizophrenia. J Clin Psychiatry (1994) 0.82
Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull (1984) 0.82
Clozapine: plasma levels and prolactin response. Psychopharmacology (Berl) (1981) 0.82
Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull (1985) 0.82
Genetic architecture of prostate cancer in the Ashkenazi Jewish population. Br J Cancer (2011) 0.82
Antibodies to acetylcholine receptors in tardive dyskinesia. Lancet (1984) 0.82
The use of clozapine in neurologic disorders. J Clin Psychiatry (1994) 0.81
The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull (1989) 0.81
Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull (1993) 0.81
A selective review of biological markers in schizophrenia. Schizophr Bull (1991) 0.81